Slide 1: Conference Call First-Half 2017 Results
Conference Call First-Half 2017 Results Joachim Kreuzburg, CEO | July 21, 2017
Slide 2: Disclaimer
Disclaimer This presentation contains statements concerning the future performance of the Sartorius Group and the Sartorius Stedim Biotech Group. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarante
Slide 3: Agenda
Agenda 01 Sartorius Group: H1 2017 Results | FY 2017 Guidance 02 Sartorius Stedim Biotech Group: H1 2017 Results | FY 2017 Guidance 03 Questions & Answers
Slide 4: H1 2017 Highlights
H1 2017 Highlights Double-digit growth in sales revenue and earnings Lab Products & Services developed highly dynamically through organic growth and expansion of its portfolio Robust performance of Bioprocess Solutions in light of normalized market growth Integration of recent acquisitions well on t
Slide 5: Double-digit sales and earnings growth
Double-digit sales and earnings growth Sartorius Group in millions of € unless otherwise specified H1 2016 H1 2017 in % in % cc 1 Sales revenue 625.4 704.1 +12.6 +11.5 Order intake 677.6 741.9 +9.5 +8.4 Underlying EBITDA2 153.4 174.5 +13.8 Underlying EBITDA2 margin 24.5 24.8 +0.3 pp Underlying EPS 3
Slide 6: All regions fuel growth; Asia most dynamic
All regions fuel growth; Asia most dynamic Americas EMEA Asia | Pacific Sales by Region € in millions € in millions € in millions in % 302.9 288.1 EMEA ~ 43% 229.0 212.3 172.2 Americas ~ 33% 125.1 € 704.1m Asia | Pacific ~ 24% H1 16 H1 17 H1 16 H1 17 H1 16 H1 17 +4.8% +5.9% +34.8% Acc. to customers‘
Slide 7: BPS: Robust development given normalized market growth
BPS: Robust development given normalized market growth Order Intake Sales Revenue Underlying EBITDA & Margin € in millions € in millions € in millions +4.4% cc +8.0% cc +10.0% +5.3% +8.8% 519.2 546.9 487.3 505.3 510.9 140.8 469.8 128.1 27.6% 27.3% H1 16 H2 16 H1 17 H1 16 H2 16 H1 17 H1 16 H1 17 Af
Slide 8: LPS: Dynamic performance fueled by organic growth and acquisitions
LPS: Dynamic performance fueled by organic growth and acquisitions Order Intake Sales Revenue Underlying EBITDA & Margin € in millions € in millions € in millions +21.1% cc +22.1% cc +33.1% +23.1% +24.1% 195.0 193.2 33.7 158.4 155.7 25.3 17.5% 16.3% H1 16 H1 17 H1 16 H1 17 H1 16 H1 17 All regions
Slide 9: Cash flow influenced by recent acquisitions
Cash flow influenced by recent acquisitions Sartorius Group € in millions H1 2016 H1 2017 in % Change in financial result largely due to valuation effects of derivatives | Underlying EBITDA 153.4 174.5 +13.8 fx loans Extraordinary items -9.9 -12.7 -28.8 Net operating cash flow driven by higher e
Slide 10: Key financial indicators remain at robust levels
Key financial indicators remain at robust levels Key Financial Indicators Net Debt and Net Debt to Underlying EBITDA Sartorius Group Dec. 31, 2016 Jun. 30, 2017 1000 3.0 3 800 2.4 2,4 Equity ratio in % 42.0 32.6 600 1.8 1,8 Net debt in millions of € 485.9 919.8 400 1.2 1,2 200 0.6 0,6 Net debt | und
Slide 11: FY 2017 guidance confirmed
FY 2017 guidance confirmed H1 2017 FY 2017 Guidance1 Sales Revenue Underlying Sales Revenue Underlying Growth1 EBITDA Margin Growth EBITDA Margin > +0.5pp Sartorius Group 11.5% 24.8% ~ 12% - 16% (FY 2016: 25.0%) ~ +0.5pp Bioprocess Solutions 8.0% 27.6% ~ 9% - 13% (FY 2016: 28.0%) 1 In constant curre
Slide 12: Agenda
Agenda 01 Sartorius Group: H1 2017 Results | FY 2017 Guidance 02 Sartorius Stedim Biotech Group: H1 2017 Results | FY 2017 Guidance 03 Questions & Answers
Slide 13: Robust development in light of normalized market growth
Robust development in light of normalized market growth Sartorius Stedim Biotech Group in millions of €, unless otherwise specified H1 2016 H1 2017 in % in % cc 1 Sales revenue 508.8 546.7 +7.5 +6.7 Order intake 558.8 583.0 +4.3 +3.5 Underlying EBITDA2 136.4 147.4 +8.1 Underlying EBITDA2 margin 26.8
Slide 14: Different development in the regions
Different development in the regions Americas EMEA Asia|Pacific Sales by Regions in € millions in € millions in € millions in % 231.5 233.2 187.9 187.1 EMEA ~ 43% 126.4 89.3 Americas ~ 34% € 546.7m H1 16 H1 17 H1 16 H1 17 H1 16 H1 17 -3.0% +2.0% +38.1% Asia | Pacific ~ 23% Acc. to customers‘ locatio
Slide 15: Robust Cash Flow Performance
Robust Cash Flow Performance Sartorius Stedim Biotech Group € in millions Net operating cash flow mainly H1 2016 H1 2017 in % driven by higher earnings and Underlying EBITDA 136.4 147.4 +8.1 lower tax payments Extraordinary items -4.8 -6.9 -44.3 Net investing cash flow primarily reflects the acq
Slide 16: Financial position remains very strong
Financial position remains very strong Key Financial Indicators Net Debt and Net Debt to Underlying EBITDA Sartorius Stedim Biotech Dec. 31, 2016 Jun. 30, 2017 180 1.5 1,5 1.5 150 1.2 1.2 1,2 Equity ratio in % 63.9 59.9 120 0.9 0,9 0.9 90 0.6 0,6 0.6 Net debt in millions of € 67.6 166.9 60 30 0.3 0.
Slide 17: Outlook for 2017 confirmed
Outlook for 2017 confirmed H1 2017 FY 2017 Guidance Sales revenue growth1 6.7% ~ 8% - 12% ~ +0.5pp1 Underlying EBITDA margin 27.0% (FY 2016: 27.5%) Capex ratio 10.8% ~ 10% - 13% 1 In constant currencies Guidance includes a good 1pp of growth expected to be contributed by the acquisition of kSep an
Slide 18: Agenda
Agenda 01 Sartorius Group: H1 2017 Results | FY 2017 Guidance 02 Sartorius Stedim Biotech Group: H1 2017 Results | FY 2017 Guidance 03 Questions & Answers
Slide 19: Thank you very much for your attention
Thank you very much for your attention